AMENDMENTS TO THE CLAIMS

Please delete claims 1-154. Please add new claims 155-172.

LISTING OF CLAIMS

155. (NEW) A modified-release tablet suitable for use in a once-daily administration of bupropion treatment regimen in patients in need of such bupropion administration wherein said modified-release tablet is bioequivalent to Welbutrin or Zyban/Wellbutrin SR tablets over a 24 hour period when said modified-release tablet is administered in a once-a-day bupropion treatment regimen to a patient in need of such bupropion administration.

156. (NEW) The modified release tablet of claim 155 which does not exhibit any food effects.

157. (NEW) The modified release tablet of claim 155 which includes a moisture barrier.

158. (NEW) The modified release tablet of claim 155 wherein at least 95% of said bupropion remains undegraded after storage of said modified-release tablet for 18 months at about 25 +/- 2 degrees C at 60% RH +/-5% RH.

159. (NEW) The modified release tablet of claim 158 which does not exhibit any food effect.

160. (NEW) The modified-release tablet of claim 155 wherein said bupropion comprise bupropion HCl.

161. (NEW) The modified release tablet of claim 155 which comprises 150 mg of said bupropion.

162. (NEW) The modified-release tablet of claim 155 which comprises 300 mg of said bupropion.

163. (NEW) The modified-release tablet of claim 157 wherein the amount of said moisture barrier constitutes no more than about 6% of the weight of said modified-release tablet.

164. (NEW) The modified-release tablet of Claim 157 wherein the amount of said moisture barrier constitutes no more than about 2.5% of the total weight of said modified-release tablet.

165. (NEW) The modified-release tablet of claim 155 which when administered in a once-daily bupropion treatment regimen to a patient in need of treatment provides a Cmax for bupropion ranging from about 60ng/ml to about 280 ng/ml at between 3 hours and 8 hours (Tmax), an AUC (0-inf) for bupropion ranging from about 800 ng.hr/ml to about 2850 ng.hr/ml.

166. (NEW) The modified release tablet of claim 165 which comprises a 300 mg dose.

167. (NEW) The modified-release tablet of claim 165 which comprises a 2X150 mg dose administered once-daily.

168. (NEW) The modified-release tablet of claim 155 which comprises a bupropion containing core which core is surrounded by a control-releasing coat that controls the release of bupropion from the modified-release tablet and a moisture barrier that inhibits the degradation of bupropion contained in said modified-release tablet.

169. (NEW) A method of treating depression which comprising administering bupropion in a once-daily treatment regimen wherein said bupropion treatment comprises once-daily administration of a modified-release tablet according to any one of claims 155-168.

170. (NEW) The method of claim 169 wherein said once-daily bupropion treatment regimen comprises administration of said modified-release tablet containing a 300 mg dose.

171. (NEW) The method of claim 169 wherein said once-daily bupropion treatment regimen comprises daily administration of 2 X150 mg of said modified-release tablet.

172. (NEW) The modified-release tablet of claim 155 which comprises:

(i) a bupropion containing core

(ii)a polymeric control release coating substantially surrounding said core; and

(iii) a polymeric moisture barrier layer substantially surrounding said polymeric release coating; wherein the polymeric constituents and the amounts thereof contained in said control-release coating and said moisture barrier layer are selected such that a modified-release tablet is obtained that is bioequivalent to Welbutrin or Zyban/Welbutrin SR tablets over a 24 hour period.